drugset / Trial / NCT03994601
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of select advanced solid tumors.
Timeline
- Start
- 2019-09-06
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986288 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Background | Regorafenib | Small molecule | — | — |